Seismic Therapeutic Reveals New Preclinical Data for S-4321 Antibody at ACR Convergence 2024

Seismic Therapeutic, Inc., a company specializing in machine learning immunology, has presented new preclinical data for its innovative treatment S-4321 at the ACR Convergence 2024. This annual meeting of the American College of Rheumatology took place in Washington, DC from November 14-19, 2024. The data showcased at this event support the potential of S-4321, a PD-1: FcγRIIb-selective bifunctional agonist antibody, for treating autoimmune diseases. Based on these promising results, Seismic Therapeutic aims to initiate a Phase 1 clinical trial of S-4321 with healthy volunteers in the first half of 2025.

S-4321 has been engineered to target the PD-1 receptor on T cells and the FcγRIIb receptor on B cells and antigen-presenting cells (APCs) without depleting cells expressing PD-1. This dual engagement mechanism is expected to enhance the therapy's efficacy in autoimmune diseases by inducing regulatory T cells and demonstrating activity in preclinical models, such as a murine model of graft versus host disease.

In a presentation titled "S-4321, a novel dual-cell bidirectional PD-1:FcγRIIb selective agonist antibody for the treatment of autoimmune disease," key findings highlighted the differentiation and potential benefits of S-4321. John Sundy, MD, PhD, Chief Medical Officer and Head of R&D at Seismic Therapeutic, emphasized the deliberate design of S-4321 to optimally agonize both PD-1 and FcγRIIb inhibitory receptors within a single molecule. According to Sundy, the unique profile of S-4321 is likely to result in superior drug activity and clinical benefits across various prevalent autoimmune diseases. The upcoming clinical trial will focus on assessing biomarkers of PD-1 agonist activity facilitated by S-4321's distinct mechanism.

In addition to the presentation on S-4321, Seismic Therapeutic also unveiled data on another promising program, S-1117. This engineered pan-IgG protease, intended for chronic administration, is set for clinical development and targets autoantibody-mediated diseases. These presentations underline Seismic Therapeutic's commitment to advancing innovative treatments for autoimmune conditions through their machine learning-driven IMPACT platform.

Seismic Therapeutic is a biotechnology company leveraging machine learning to revolutionize the discovery and development of immunology therapies. The company's robust preclinical pipeline includes both best-in-class and first-in-class biologics aimed at controlling dysregulated adaptive immunity to address multiple autoimmune diseases. Situated in the Boston biotechnology hub, Seismic Therapeutic is backed by a consortium of leading life sciences investors.

The company’s innovative approach integrates machine learning into the immunology field, promising a transformative impact on how therapies are developed and discovered. By focusing on cutting-edge biologics derived from their IMPACT platform, Seismic Therapeutic is poised to address significant unmet needs in the treatment of autoimmune diseases.

Seismic Therapeutic's dedication to innovation and excellence in biotechnology continues to drive the development of pioneering therapies that hold the potential to significantly improve patient outcomes in autoimmune diseases. The ongoing research and forthcoming clinical trials of S-4321 and S-1117 are anticipated to further validate the effectiveness of their novel therapeutic strategies.